First-line trastuzumab deruxtecan extends progression-free survival in HER2-mutant lung cancer
The Phase 3 DESTINY-Lung04 trial reports that first-line single-agent trastuzumab deruxtecan significantly improved progression-free survival and response rates versus pembrolizumab ...
